FDA will undertake steps to accelerate the process of developing biosimilars, while also reducing development costs. 

Read this month’s pharma news roundup, featuring brain-computer interfaces, a new world record and a cost-effectiveness conundrum.

The UK government has extended the deadline for organisations to submit notice to leave the scheme by two weeks.

Novartis to acquire Avidity Biosciences for $12bn, boosting its RNA neuromuscular pipeline as pharma M&A heats up in the RNA space.

Google’s Quantum Echoes breakthrough could revolutionise drug discovery, offering faster, more precise ways to design new medicines.

CSL Seqirus real-world study finds cell-based flu vaccines offer stronger protection than egg-based options in 2023/24 season.

Lundbeck is partnering with Contera Pharma to accelerate RNA-targeted drug discovery for serious neurological conditions.

Injectable HIV PrEP marks a breakthrough in prevention, providing a new option for patients in England unable to take daily pills.